Acumen Pharmaceuticals ABOS Income Statement (2020-2026)

NASDAQ ABOS
$3.19 +0.04 (+1.27%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
40.47M20.06M40.47M40.50M40.50M41.03M41.03M41.03M57.91M57.91M60.08M60.08M60.08M60.09M60.57M60.57M60.57M60.58M72.23M72.31M
Operating items
Research & Development (Quarter)
1.80M5.67M5.99M7.32M8.31M10.75M8.71M9.13M11.18M13.29M12.45M19.53M27.25M34.57M25.27M37.12M21.97M20.53M16.48M27.81M
Selling, General & Administrative (Quarter)
2.13M2.74M3.22M3.09M3.06M3.50M4.42M4.34M4.86M5.19M5.33M4.85M5.02M5.03M5.10M4.62M4.54M4.67M4.67M4.75M
Operating Expenses (Quarter)
3.94M8.41M9.21M10.41M11.37M14.25M13.13M13.48M16.04M18.49M17.77M24.38M32.27M39.60M30.37M41.75M26.51M25.20M21.15M32.56M
Operating Income (Quarter)
-3.94M-8.41M-9.21M-10.41M-11.37M-14.25M-13.13M-13.48M-16.04M-18.49M-17.77M-24.38M-32.27M-39.60M-30.37M-41.75M-26.51M-25.20M-21.15M-32.56M
EBIT (Quarter)
-3.94M-8.41M-9.21M-10.41M-11.37M-14.25M-13.13M-13.48M-16.04M-18.49M-17.77M-24.38M-32.27M-39.60M-30.37M-41.75M-26.51M-25.20M-21.15M-32.56M
Non-operating items
Interest & Investment Income (Quarter)
0.04M1.88M3.12M3.95M4.00M3.82M3.50M2.99M2.47M2.02M1.64M1.32M1.06M1.11M
Other Non Operating Income (Quarter)
0.02M0.00M0.00M-0.00M-0.01M-0.00M-0.02M-0.05M-0.07M-0.01M-1.19M0.19M-0.04M-0.07M-0.20M0.46M-0.16M
Non Operating Income (Quarter)
0.01M0.06M0.08M0.26M0.66M1.38M1.83M1.87M3.08M1.99M2.90M3.84M2.50M2.44M1.57M0.80M0.06M0.06M0.41M-0.16M
Net income details
EBT (Quarter)
-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-38.42M-28.92M-40.78M-25.94M-24.61M-21.15M-32.54M
Profit After Tax (Quarter)
-3.90M-8.58M-9.71M-10.15M-10.71M-12.87M-11.31M-11.73M-12.96M-16.50M-15.33M-20.56M-29.77M-37.72M-28.73M-40.95M-26.36M-25.16M-20.80M-32.75M
Income from Non-Controlling Interests (Quarter)
-0.03M-0.20M-0.58M-0.15M0.21M0.23M-0.12M0.14M0.82M-0.46M-0.02M0.68M-0.57M0.06M0.01M0.09M-0.03M-0.06M-0.03M
Income from Continuing Operations (Quarter)
-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-38.42M-28.92M-40.78M-25.94M-24.61M-21.15M-32.54M
Consolidated Net Income (Quarter)
-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-38.42M-28.92M-40.78M-25.94M-24.61M-21.15M-32.54M
Income towards Parent Company (Quarter)
-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-38.42M-28.92M-40.78M-25.94M-24.61M-21.15M-32.54M
Net Income towards Common Stockholders (Quarter)
-3.92M-8.39M-9.24M-22.91M-51.19M-14.13M-13.18M-11.63M-12.91M-14.70M-14.77M-21.57M-29.79M-38.42M-28.92M-40.78M-25.94M-24.61M-21.15M-32.54M
Additional items
EPS (Basic) (Quarter)
-0.10-0.42-0.23-0.57-1.26-0.35-0.32-0.28-0.24-0.30-0.25-0.36-0.50-0.64-0.48-0.67-0.43-0.41-0.33-0.51
EPS (Diluted) (Quarter)
-0.10-0.42-0.23-0.57-1.26-0.35-0.32-0.28-0.24-0.30-0.25-0.36-0.50-0.64-0.48-0.67-0.43-0.41-0.33-0.51
Shares Outstanding (Quarter)
38.27M20.06M40.47M40.50M40.50M40.60M41.03M41.03M54.23M48.61M59.81M60.08M60.08M60.01M60.53M60.57M60.57M60.56M63.22M63.22M
Shares Outstanding (Diluted) (Quarter)
38.27M20.06M40.47M40.50M40.50M40.60M41.03M41.03M54.23M48.61M59.81M60.08M60.08M60.01M60.53M60.57M60.57M60.56M63.22M63.22M
EBITDA (Quarter)
-3.94M-8.41M-9.21M-10.41M-11.37M-14.25M-13.13M-13.48M-16.04M-18.49M-17.77M-24.38M-32.27M-39.60M-30.37M-41.75M-26.51M-25.20M-21.15M
Interest Expenses (Quarter)
0.02M-0.02M0.04M12.50M39.82M-0.11M0.04M0.04M0.17M1.00M1.00M1.03M1.82M1.02M1.05M1.07M0.73M1.07M